<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Postma, D.S.</title>
    <link>http://repub.eur.nl/res/aut/2381/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Genetics of onset of asthma (Article)</title>
      <link>http://repub.eur.nl/res/pub/39370/</link>
      <pubDate>2013-04-01T00:00:00Z</pubDate>
      <description>Purpose of Review: Most asthma starts early in life. Defining phenotypes of asthma at this age is difficult as many preschool children have asthma-like respiratory symptoms. This review discusses progress in defining early wheezing phenotypes and describes genetic factors associated with the age of onset of asthma. Recent Findings: Latent class analyses confirmed transient and persistent wheezing phenotypes, and identified a novel intermediate-onset wheezing phenotype that was strongly associated with atopy and asthma at age 8 years. However, no single cross-sectional or longitudinal definition of respiratory symptoms in childhood strongly predicts asthma later in life. Genome-wide association (GWA) studies have identified a locus on chromosome 17q12-21 (encoding ORMDL3 and GSDMB) as a risk factor for predominantly childhood-onset asthma, but not for atopy, and overall not for adult-onset asthma. Other loci found by GWA studies appear to increase asthma risk both in children and adults. Atopy genes do not explain early-onset asthma. Summary: Although most asthma starts early in life, no valid test is able to identify asthma at that age period. GWA studies have provided more insight into the unique and common genetic origins of adult-onset and childhood-onset asthma. The 17q12-21 locus is predominantly associated with childhood-onset asthma. Copyright </description>
    </item> <item>
      <title>Response to childrenê 1/4s home blood pressure and growth environment (Article)</title>
      <link>http://repub.eur.nl/res/pub/39624/</link>
      <pubDate>2013-04-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Blood pressure in 12-year-old children is associated with fatty acid composition of human milk: The prevention and incidence of asthma and mite allergy birth cohort (Article)</title>
      <link>http://repub.eur.nl/res/pub/37398/</link>
      <pubDate>2012-10-01T00:00:00Z</pubDate>
      <description>Breastfed individuals have a lower blood pressure than formula-fed individuals. Supplementation with n-3 long-chain polyunsaturated fatty acids in adults is also associated with a lower blood pressure. We studied whether children receiving human milk with a relatively high content of n-3 long-chain polyunsaturated fatty acids have a lower blood pressure at age 12 years, and, if so, whether this association is explained by the n-3 long-chain polyunsaturated fatty acids content in erythrocyte membranes at age 12 years. Within a 12-year follow-up of a population-based birth cohort, we compared blood pressure of 205 never-breastfed children and 109 children who had fatty acid composition of their mothers' breast milk measured during lactation. In addition, 973 children had information on erythrocyte fatty acid composition and blood pressure at age 12 years. Children who received human milk with an n-3 long-chain polyunsaturated fatty acids content above the median (ie, 0.51 weight percentage) had a 4.79-mm Hg lower systolic (95% CI, -7.64 to -1.94) and a 2.47-mm Hg lower diastolic (95% CI, -4.45 to -0.49) blood pressure at age 12 years than never-breastfed children. N-3 long-chain polyunsaturated fatty acids levels in human milk below the median value and current n-3 long-chain polyunsaturated fatty acid status were not associated with blood pressure at age 12 years. Thus, a relatively high content of n-3 long-chain polyunsaturated fatty acids in human milk is associated with a lower blood pressure in children at age 12 years, a finding not explained by current n-3 long-chain polyunsaturated fatty acids status. </description>
    </item> <item>
      <title>Opposite effects of allergy prevention depending on CD14 rs2569190 genotype in 3 intervention studies (Article)</title>
      <link>http://repub.eur.nl/res/pub/31999/</link>
      <pubDate>2012-01-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Childhood overweight and asthma symptoms, the role of pro-inflammatory proteins (Article)</title>
      <link>http://repub.eur.nl/res/pub/34786/</link>
      <pubDate>2012-01-01T00:00:00Z</pubDate>
      <description>Background Systemic inflammation is suggested as a mechanism by which overweight might induce asthma. However, few studies have linked childhood overweight, inflammation and asthma. Objective To study the association between body mass index (BMI), asthma symptoms and pro-inflammatory proteins. Methods High-sensitivity C-reactive protein (hs-CRP), complement factor 3 (C3) and 4 (C4) concentrations, and body weight and height were available for 359 4-year-old children participating in the Prevention and Incidence of Asthma and Mite Allergy birth cohort study. Data on asthma symptoms were obtained by yearly questionnaires. Logistic regression and generalized estimating equations were used to analyse the cross-sectional and prospective associations between BMI, asthma symptoms and pro-inflammatory proteins. Results BMI was associated with asthma symptoms {odds ratio [OR] 1.43 [95% confidence interval (CI): 1.08-1.88] per BMI standard deviation scores [SDS]}. The inclusion of hs-CRP, C3 and C4 in the statistical models did not change this association. C3 was cross-sectionally associated with frequent asthma symptoms [OR per interquartile range of C3: 1.97 (95% CI: 1.20-3.24)] and prospectively with asthma symptoms [OR: 1.48 (95%CI: 1.04-2.09)], independent of BMI SDS. Conclusions and Clinical Relevance We showed no evidence for a role of hs-CRP, C3 and C4 in the association between BMI and asthma symptoms. C3 concentrations were associated with (frequent) asthma symptoms, independent of BMI. </description>
    </item> <item>
      <title>Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function (Article)</title>
      <link>http://repub.eur.nl/res/pub/34149/</link>
      <pubDate>2011-11-01T00:00:00Z</pubDate>
      <description>Pulmonary function measures reflect respiratory health and are used in the diagnosis of chronic obstructive pulmonary disease. We tested genome-wide association with forced expiratory volume in 1 second and the ratio of forced expiratory volume in 1 second to forced vital capacity in 48,201 individuals of European ancestry with follow up of the top associations in up to an additional 46,411 individuals. We identified new regions showing association (combined P &lt; 5 ×-10-8) with pulmonary function in or near MFAP2, TGFB2, HDAC4, RARB, MECOM (also known as EVI1), SPATA9, ARMC2, NCR3, ZKSCAN3, CDC123, C10orf11, LRP1, CCDC38, MMP15, CFDP1 and KCNE2. Identification of these 16 new loci may provide insight into the molecular mechanisms regulating pulmonary function and into molecular targets for future therapy to alleviate reduced lung function. </description>
    </item> <item>
      <title>CT-quantified emphysema in male heavy smokers: Association with lung function decline (Article)</title>
      <link>http://repub.eur.nl/res/pub/33301/</link>
      <pubDate>2011-09-01T00:00:00Z</pubDate>
      <description>Background: Emphysema and small airway disease both contribute to chronic obstructive pulmonary disease (COPD), a disease characterised by accelerated decline in lung function. The association between the extent of emphysema in male current and former smokers and lung function decline was investigated. Methods: Current and former heavy smokers participating in a lung cancer screening trial were recruited to the study and all underwent CT. Spirometry was performed at baseline and at 3-year follow-up. The 15th percentile (Perc15) was used to assess the severity of emphysema. Results: 2085 men of mean age 59.8 years participated in the study. Mean (SD) baseline Perc15 was -934.9 (19.5) HU. A lower Perc15 value correlated with a lower forced expiratory volume in 1 s (FEV1) at baseline (r=0.12, p&lt;0.001). Linear mixed model analysis showed that a lower Perc15 was significantly related to a greater decline in FEV1 after follow-up (p&lt;0.001). Participants without baseline airway obstruction who developed it after follow-up had significantly lower mean (SD) Perc15 values at baseline than those who did not develop obstruction (-934.2 (17.1) HU vs -930.2 (19.7) HU, p&lt;0.001). Conclusion: Greater baseline severity of CT-detected emphysema is related to lower baseline lung function and greater rates of lung function decline, even in those without airway obstruction. CT-detected emphysema aids in identifying non-obstructed male smokers who will develop airflow obstruction.</description>
    </item> <item>
      <title>Reply (Article)</title>
      <link>http://repub.eur.nl/res/pub/31253/</link>
      <pubDate>2011-08-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Uncontrolled asthma at age 8: The importance of parental perception towards medication (Article)</title>
      <link>http://repub.eur.nl/res/pub/34039/</link>
      <pubDate>2011-08-01T00:00:00Z</pubDate>
      <description>Background: Despite existing effective treatment options, asthma is uncontrolled in a considerable proportion of patients. The aim of this study was to identify determinants of uncontrolled asthma at age 8 in children participating in the PIAMA birth cohort study. Methods: One hundred seventy children using inhaled corticosteroids in the previous 12months at age 8 were included. Uncontrolled asthma was defined as: ≥3 items present in the past month: (1) day-time or (2) night-time asthma symptoms, (3) limitations in activities, (4) rescue medication use, (5) FEV1&lt;80% predicted and (6) unscheduled physician visits because of asthma. Binomial regression was performed to study five groups of determinants representing asthma control: child and parental characteristics, environmental factors, therapy adherence and parental perception towards medication use (Beliefs about Medicines Questionnaire). Results: Seventy seven children (45%) had uncontrolled asthma. Low maternal education (RR 1.6, 95% CI: 1.0-2.4) was associated with uncontrolled asthma. Parental necessity beliefs about medication use to maintain present and future health and parental concerns about potential adverse consequences of medication were also associated with uncontrolled asthma (RR 1.6, 95% CI: 1.1-2.2; and 1.6, 95% CI: 1.0-2.5, respectively). Conclusions: Environmental factors and therapy adherence were not associated with asthma control. In our cohort, uncontrolled asthma is associated with low maternal education and with strong parental beliefs about medication necessity and higher concern about potential side effects of medication. </description>
    </item> <item>
      <title>Comparison of childhood wheezing phenotypes in 2 birth cohorts: ALSPAC and PIAMA (Article)</title>
      <link>http://repub.eur.nl/res/pub/33431/</link>
      <pubDate>2011-06-01T00:00:00Z</pubDate>
      <description>Background: Asthma has its origins in early childhood, but different patterns of childhood wheezing vary in their associations with subsequent asthma, atopy, and bronchial hyperresponsiveness (BHR). Novel wheezing phenotypes have been identified on the basis of analyses of longitudinal data from the Avon Longitudinal Study of Parents And Children (ALSPAC). It is unclear whether these phenotypes can be replicated in other birth cohorts. Objective: To compare wheezing phenotypes identified in the first 8 years of life in the ALSPAC study and the Prevention and Incidence of Asthma and Mite Allergy (PIAMA) study. Methods: We used longitudinal latent class analysis to identify phenotypes on the basis of repeated reports of wheezing from 0 to 8 years in 5760 children from the ALSPAC study and 2810 children from the PIAMA study. Phenotypes were compared between cohorts. Associations with asthma, atopy, BHR, and lung function were analyzed by using weighted regression analyses. Results: The model with the best fit to PIAMA data in the first 8 years of life was a 5-class model. Phenotypes identified in the PIAMA study had wheezing patterns that were similar to those previously reported in ALSPAC, adding further evidence to the existence of an intermediate-onset phenotype with onset of wheeze after 2 years of age. Associations with asthma, atopy, BHR, and lung function were remarkably similar in the 2 cohorts. Conclusion: Wheezing phenotypes identified by using longitudinal latent class analysis were comparable in 2 large birth cohorts. Study of genetic and environmental factors associated with different phenotypes may help elucidate the origins of asthma. </description>
    </item> <item>
      <title>Interleukin-1 receptor-like 1 polymorphisms are associated with serum IL1RL1-a, eosinophils, and asthma in childhood (Article)</title>
      <link>http://repub.eur.nl/res/pub/33512/</link>
      <pubDate>2011-03-01T00:00:00Z</pubDate>
      <description>Background: IL-1 receptor-like 1 (IL1RL1) is a membrane receptor involved in TH2 inflammatory responses and eosinophilia. Single nucleotide polymorphisms (SNPs) in IL1RL1 have been associated with blood eosinophil counts in a genome-wide association study and with asthma in family-based and case-control studies. Objective: We assessed in the prospective birth cohort Prevention and Incidence of Asthma and Mite Allergy (PIAMA) whether IL1RL1 SNPs associate with levels of its soluble transcript IL1RL1 (IL1RL1-a) in serum, blood eosinophil counts, and asthma prevalence from birth to age 8 years, and whether IL1RL1-a serum levels associate with blood eosinophil counts. Methods: Fifteen IL1RL1 SNPs were genotyped. Serum IL1RL1-a levels were measured in 2 independent subsets within PIAMA, at 4 and 8 years. Blood eosinophil counts were measured in 4-year-old children. Results: In 2 independent subsets of children, 13 of 15 SNPs were associated with serum IL1RL1-a levels at ages 4 and 8 years with a consistent direction of effect for each allele. Rs11685480 allele A and rs1420102 allele A were significantly associated with lower numbers of blood eosinophils. In the total cohort, rs1041973 allele A was associated with a decreased risk of developing asthma (odds ratio, 0.70; 95% CI, 0.54-0.90). Rs1420101, recently identified in a genome-wide association study in the Icelandic population, was not associated with asthma in this study. IL1RL1-a levels were not associated with eosinophil counts. Conclusion: We demonstrate that IL1RL1 polymorphisms are associated with serum IL1RL1-a, blood eosinophils, and asthma in childhood. </description>
    </item> <item>
      <title>High agreement between parental reported inhaled corticosteroid use and pharmacy prescription data (Article)</title>
      <link>http://repub.eur.nl/res/pub/21604/</link>
      <pubDate>2010-11-01T00:00:00Z</pubDate>
      <description>Purpose: This study was conducted to assess the validity of parental reported use of inhaled corticosteroids (ICS) in children. Methods: ICS users were identified within the Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort study and the PIAMA pharmacy sub-cohort which is nested within the PIAMA study. Complete medication histories were available for the first 8 years of life for children within the PIAMA pharmacy sub-cohort. Parental reported ICS use was measured by using data from questionnaires. ICS use in the pharmacy records was determined by using the Anatomical Therapeutic Chemical (ATC) codes. The proportion of overall agreement and kappa statistics with their corresponding 95% confidence intervals were calculated to quantify agreement between self-reported medication use and pharmacy prescription data. Results: At all ages overall agreement was very high (&gt;97%) and Cohen's kappa's ranged from 0.80 to 0.88 which also reflects excellent agreement between parental reported use of ICS and pharmacy prescription data. Conclusions: Our finding suggests that parental report of medication use is a reliable source of data to asses ICS use in children. The questionnaire-based medication data collected within the PIAMA study can be used to study asthma medication use in a large group of children.</description>
    </item> <item>
      <title>Patterns of asthma medication use: Early asthma therapy initiation and asthma outcomes at age 8 (Article)</title>
      <link>http://repub.eur.nl/res/pub/28284/</link>
      <pubDate>2010-10-01T00:00:00Z</pubDate>
      <description>Wheeze has many underlying pathophysiologies in childhood, but is the main reason for anti-asthma drugs prescription. This study was conducted to describe asthma medication use patterns among children in their first eight years of life. Longitudinal medication use data from 777 children participating in the PIAMA study were used. Medication patterns were described for four groups that started therapy before the third birthday, when the peak in prescriptions occurred in our cohort; short-acting β-agonists (SABA), inhaled corticosteroids (ICS), SABA + ICS or none of these. One third (n = 255) of the children received a first SABA or ICS prescription before age 8. Only three children (1.2%) used medication continuously during follow-up. Of the children who started SABA, 53.8% discontinued within 1-2 years. Of the children who started ICS before age 3, 42.1% discontinued within 1-2 years and 31.6% received additional SABA. 41.5% of the children who started SABA + ICS used this short-term (≤1-2 years) and 21.5% long-term (≥3 years). Fifteen percent of children who did not start asthma therapy in their first 3 years of life did receive prescriptions between age 3 and 8. Children prescribed SABA + ICS before age 3 had the highest prevalence of hyper responsiveness at age 8, and similar prevalence of atopy as the other groups. Asthma medication is prescribed frequently in the first 8 years of life, particularly before age 3, and only few children use it continuously. ICS and SABA prescription occurs especially in those who were more likely to develop signs of asthma at age 8. </description>
    </item> <item>
      <title>Toll-like receptor 2 and 4 genes influence susceptibility to adverse effects of traffic-related air pollution on childhood asthma (Article)</title>
      <link>http://repub.eur.nl/res/pub/27473/</link>
      <pubDate>2010-08-01T00:00:00Z</pubDate>
      <description>Background: Epidemiological studies have reported adverse effects of ambient air pollution on the prevalence of asthma. Laboratory studies have suggested that innate immune responses are involved. Objective: A study was undertaken to determine whether the Toll-like receptor 2 and 4 genes (TLR2 and TLR4) influence the susceptibility to adverse effects of traffic-related air pollution with respect to the prevalence of childhood asthma. Methods: Haplotype tagging single nucleotide polymorphisms (SNPs) in the TLR2 (n=4) and TLR4 genes (n=9) were genotyped in 916 children from the Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort. Exposure to particulate matter (PM2.5), soot and nitrogen dioxide (NO2) at the birth address was estimated by land use regression models. Interactions between levels of pollutants and SNPs in relation to annual questionnaire reports of asthma diagnosis and symptoms from birth up to 8 years of age were analysed longitudinally by generalised estimating equations. Results: Two TLR2 SNPs and four TLR4 SNPs significantly modified the effect of air pollution on the prevalence of doctor-diagnosed asthma from birth up to 8 years of age. The risk of having doctor-diagnosed asthma increased with increasing PM2.5levels in children with at least one copy of the TLR2 rs4696480 A allele (OR 2.0 (95% CI 1.2 to 3.1) for an interquartile range increase in exposure). Similar observations were present with the following TLR4 genotypes: rs2770150 TC (OR 2.0 (95% CI 1.1 to 3.6)), rs10759931 GG (OR 2.6 (95% CI 1.4 to 4.9)), rs6478317 GG (OR 2.2 (95% CI 1.2 to 4.3)), rs10759932 CT or CC (OR 2.9 (95% CI 1.2 to 6.9)) and rs1927911 TT (OR 4.4 (95% CI 1.7 to 11.7)). Conclusions: Variant alleles of TLR2 and TLR4 genes influence the susceptibility to adverse effects of traffic-related air pollution on childhood asthma.</description>
    </item> <item>
      <title>Variants in ADCY5 and near CCNL1 are associated with fetal growth and birth weight (Article)</title>
      <link>http://repub.eur.nl/res/pub/28299/</link>
      <pubDate>2010-05-01T00:00:00Z</pubDate>
      <description>To identify genetic variants associated with birth weight, we meta-analyzed six genome-wide association (GWA) studies (n = 10,623 Europeans from pregnancy/birth cohorts) and followed up two lead signals in 13 replication studies (n = 27,591). rs900400 near LEKR1 and CCNL1 (P = 2 × 10 35) and rs9883204 in ADCY5 (P = 7 × 10 15) were robustly associated with birth weight. Correlated SNPs in ADCY5 were recently implicated in regulation of glucose levels and susceptibility to type 2 diabetes, providing evidence that the well-described association between lower birth weight and subsequent type 2 diabetes has a genetic component, distinct from the proposed role of programming by maternal nutrition. Using data from both SNPs, we found that the 9% of Europeans carrying four birth weight-lowering alleles were, on average, 113g (95% CI 89-137g) lighter at birth than the 24% with zero or one alleles (P trend = 7 × 10 30). The impact on birth weight is similar to that of a mother smoking 4-5 cigarettes per day in the third trimester of pregnancy. </description>
    </item> <item>
      <title>Maternal overweight before pregnancy and asthma in offspring followed for 8 years (Article)</title>
      <link>http://repub.eur.nl/res/pub/27901/</link>
      <pubDate>2010-04-01T00:00:00Z</pubDate>
      <description>Objective:The aim of this study was to investigate the association between maternal overweight before pregnancy and offspring asthma in an ongoing birth cohort study. Maternal overweight may affect the pulmonary and immunological development of the fetus in utero because of the increased levels of inflammatory factors associated with being overweight and thereby increase the asthma risk in childhood.Design:Birth cohort study with follow-up until 8 years of age.Subjects:The study population included 3963 children and their mothers who participated in the Prevention and Incidence of Asthma and Mite Allergy study.Measurements:Maternal overweight before pregnancy was defined as a body mass index (BMI) above 25 kg m 2. Data on wheeze, dyspnea and prescription of inhaled corticosteroids of the child were reported yearly by the parents in a questionnaire. Sensitization to inhalant allergens and bronchial hyperresponsiveness (BHR) were determined at 8 years. Effect modification by predisposition for asthma in the child was tested. Data were analyzed by logistic regression and generalized estimating equations analyses.Results:At 8 years, 14.4% (n571) of the children had asthma. In total, 20.9% (n830) of the mothers were overweight before pregnancy. In children predisposed for asthma (n1058), maternal overweight before pregnancy was associated with an increased risk of asthma in the child at 8 years (OR1.52, 95% CI: 1.05-2.18) after adjustment for confounding factors, birth weight and the child's BMI. No association was observed in children without a predisposition (OR0.86, 95% CI: 0.60-1.23). There was no association with sensitization or BHR.Conclusion: Children with a predisposition for asthma may have a higher risk to develop asthma during childhood when their mothers are overweight before pregnancy, irrespective of the child's BMI. </description>
    </item> <item>
      <title>Novel strategy to identify genetic risk factors for COPD severity: A genetic isolate (Article)</title>
      <link>http://repub.eur.nl/res/pub/28114/</link>
      <pubDate>2010-04-01T00:00:00Z</pubDate>
      <description>Studies using genetic isolates with limited genetic variation may be useful in chronic obstructive pulmonary disease (COPD) genetics, but are thus far lacking. The associations between single nucleotide polymorphisms (SNPs) in candidate genes and lung function in COPD were studied in a genetic isolate. In 91 subjects with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage ≥1 COPD, who were members of an extended pedigree including 6,175 people from the Genetic Research in Isolated Populations study, 32 SNPs were analysed in 13 candidate genes: a disintegrin and metalloprotease domain 33 gene (ADAM33), transforming growth factor-β1 gene (TGFB1), matrix metalloprotease-1 gene (MMP1), MMP2, MMP9, MMP12, tissue inhibitor of metalloprotease-1 gene (TIMP1), surfactant protein A1 gene (SFTPA1), SFTPA2, SFTPB, SFTPD, glutathione S-transferase P1 gene (GSTP1), and haem oxygenase 1 gene (HMOX1). Their relation to forced expiratory volume in 1 s (FEV1), inspiratory vital capacity (IVC) and FEV1/IVC were studied using restricted maximum likelihood linear mixed modelling, accounting for pedigree structure. Significant associations were replicated in the general Vlagtwedde/Vlaardingen study. Six SNPs in TGFB1, SFTPA1, SFTPA2 and SFTPD were significantly associated with FEV1/IVC in subjects with GOLD stage ≥1 COPD. Two SNPs in TGFB1 (C to T substitution at nucleotide -509 and substitution of leucine 10 with proline (Leu10Pro)), Leu50Val in SFTPA1 and Ala160Thr in SFTPD showed evidence suggestive of association with FEV1/IVC in subjects with GOLD stage ≥2 COPD. The TGFB1 associations were replicated in GOLD stage o2 patients from the Vlagtwedde/ Vlaardingen population, with similar effect sizes. It was shown that a genetic isolate can be used to determine the genetics of lung function, which can be replicated in COPD patients from an independent population. Copyright</description>
    </item> <item>
      <title>The 15q24/25 susceptibility variant for lung cancer and chronic obstructive pulmonary disease is associated with emphysema (Article)</title>
      <link>http://repub.eur.nl/res/pub/19208/</link>
      <pubDate>2010-03-01T00:00:00Z</pubDate>
      <description>Rationale: Genome-wide association studies have identified genetic variants in the nicotinic acetylcholine receptor (nAChR) on chromosome 15q24/25 as a risk for nicotine dependence, lung cancer, and chronic obstructive pulmonary disease (COPD). Assessment of bronchial obstruction by spirometry, typically used for diagnosing COPD, fails, however, to detect emphysema. Objectives: To determine the association of the 15q24/25 locus with emphysema. Methods: The rs1051730 variant on 15q24/25 was genotyped in two independent white cohorts of 661 and 456 heavy smokers. Participants underwent pulmonary function tests and computed tomography (CT) of the chest, and took questionnaires assessing smoking behavior and health status. Measurements and Main Results: The rs1051730 A-allele correlated with reduced FEV1 and with increased susceptibility for bronchial obstruction with a pooled odds ratio (OR) of 1.33 (95% confidence interval [CI] = 1.11-1.61; P = 0.0026). In both studies a correlation between the rs1051730 A-allele and lung diffusing capacity (DLCO) and diffusing capacity per unit alveolar volume (KCO) was observed. Consistently, the rs1051730 A-allele conferred increased risk for emphysema as assessed by CT (P = 0.0097 and P = 0.019), with a pooledORof 1.39 (CI = 1.15-1.68; P = 0.00051). Visualemphysema scores and scores based on densities quantified on CT were more pronounced in A-allele carriers, indicating that rs1051730 correlates with the severity of emphysema. Conclusions: The 15q24/25 locus in nAChR is associated with the presence and severity of emphysema. This association was independent of pack-years smoking, suggesting that nAChR is causally involved in alveolar destruction as a potentially shared pathogenic mechanism in lung cancer and COPD.</description>
    </item> <item>
      <title>Asthma therapy during the first 8 years of life: A pIAMA cohort study (Article)</title>
      <link>http://repub.eur.nl/res/pub/19875/</link>
      <pubDate>2010-03-01T00:00:00Z</pubDate>
      <description>Objective. Many studies evaluated asthma medication use in children in a cross-sectional manner, yet little is known about longitudinal use patterns. This study describes the formation of a longitudinal data set on asthma medication use and shows first results regarding the prevalence and incidence of medication use. Methods. The PIAMA (Prevention and Incidence of Asthma and Mite Allergy) study is a prospective birth cohort study among 3963 Dutch children. Recruitment took place in 1996-1997. The data of the PIAMA birth cohort study were complemented with pharmacy data. Prescription information of family members was used to determine whether medication histories were complete from birth until age 8. The prevalence and incidence of asthma medication use was studied in children for whom complete medication histories were available. Results. A first prescription for asthma medication was filled before age 8 by 280 (36%) children, with 88% starting therapy before age 5. Of all children who started therapy, 91.1% received short-acting β2-agonists and 61.1% inhaled corticosteroids. Conclusion. The applied method of data collection rendered a data set including 777 children with complete medication histories for their first 8 years of life. This data set provides the opportunity to study longitudinal medication use patterns. First analyses show that asthma medication is initiated in a rather high percentage of children in this cohort and mainly at an age at which an asthma diagnosis cannot yet be firmly established.</description>
    </item> <item>
      <title>Sex differences in asthma during the first 8 years of life: The Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort study (Letter To Editor)</title>
      <link>http://repub.eur.nl/res/pub/21795/</link>
      <pubDate>2010-01-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Filaggrin mutations in the onset of eczema, sensitization, asthma, hay fever and the interaction with cat exposure (Article)</title>
      <link>http://repub.eur.nl/res/pub/24794/</link>
      <pubDate>2009-12-01T00:00:00Z</pubDate>
      <description>Background: Filaggrin gene (FLG) mutations contribute to the development of eczema and asthma, but their contribution to sensitization and hay fever remains unclear. Methods: FLG mutations R501X, 2282del4 and R2447X were genotyped in the Prevention and Incidence of Asthma and Mite Allergy birth cohort (n = 934) to evaluate longitudinally, for up to 8 years, their association with eczema, sensitization, asthma, hay fever and their interaction with cat exposure. Results: The combined FLG mutations were significantly associated with eczema at all ages when occurring in the first year of life (OR = 2.0; 95% CI: 1.4-2.8). Combined FLG mutations were associated with both atopic and nonatopic eczema, as well as asthma (OR = 3.7; 95% CI: 1.8-7.5). When the FLG 2282del4 mutation was analysed separately, it was significantly associated with the development of eczema during the first year, having eczema up to 8 years and sensitization at the age of 8 years, which was enhanced by early-life cat exposure (ORs being 8.2; 95% CI: 2.6-25.9, 6.0; 95% CI: 3.2-11.3 and 5.4; 95% CI: 1.2-23.6 respectively). FLG 2282del4 was significantly associated with hay fever from the age 5 years onwards (OR = 3.9; 95% CI: 1.5-10.5). Conclusions: FLG mutations are associated both with atopic and nonatopic eczema starting in the first year of life. FLG mutations combined with eczema in the first year of life are associated with a later development of asthma and hay fever, a clear example of the atopic march. We confirm that cat exposure enhances the effect of a FLG mutation on the development of eczema and sensitization. </description>
    </item> <item>
      <title>Prevalence of antibodies against Ascaris suum and its association with allergic manifestations in 4-year-old children in the Netherlands: the PIAMA birth cohort study (Article)</title>
      <link>http://repub.eur.nl/res/pub/16732/</link>
      <pubDate>2009-11-01T00:00:00Z</pubDate>
      <description>The association between helminth infections and childhood atopic diseases remains controversial. The majority of studies have been carried out in tropical areas, whereas less information is available from western countries with low intensity of helminth infections. In the Netherlands, the infection of pigs with Ascaris suum is very common, particularly on pig farms with outdoor facilities. This helminth can also infect humans, causing visceral larva migrans. This study aims at determining the prevalence of antibodies against A. suum and its association with allergic symptoms and sensitisation in a population of 4-year-old children living in the Netherlands. Blood samples from 629 children from the prospective birth cohort Prevention and Incidence of Asthma and Mite Allergy (PIAMA) study were examined for Ascaris antibodies. Data on allergic symptoms and sensitisation were collected using questionnaires and radioallergosorbent tests (RAST). A total of 45 out of 629 (7%) were found to be Ascaris-seropositive. In addition, a positive association between Ascaris seropositivity and wheeze in the last year, doctor-diagnosed asthma and food and aero-allergen sensitisation was found. These results support the hypothesis that low-level or transient infection with helminths enhances allergic reactivity.</description>
    </item> <item>
      <title>Predicting the long-term prognosis of children with symptoms suggestive of asthma at preschool age (Article)</title>
      <link>http://repub.eur.nl/res/pub/17097/</link>
      <pubDate>2009-11-01T00:00:00Z</pubDate>
      <description>Background: Clinicians have difficulty in diagnosing asthma in preschool children with suggestive symptoms. Objective: We sought to develop a clinical asthma prediction score for preschool children who have asthma-like symptoms for the first time. Methods: The Prevalence and Incidence of Asthma and Mite Allergy birth cohort followed 3,963 children for 8 years. Between 0 and 4 years of age, 2,171 (55%) children reported "wheezing," "coughing at night without a cold," or both. In these children possible predictor variables for asthma were assessed at the age respiratory symptoms were first reported. Asthma was defined as wheezing, inhaled steroid prescription, or a doctor's diagnosis of asthma at both age 7 and 8 years of age. Results: Eleven percent of children with symptoms at 0 to 4 years of age had asthma at 7 to 8 years of age. Eight clinical parameters independently predicted asthma at 7 to 8 years of age: male sex, postterm delivery, parental education and inhaled medication, wheezing frequency, wheeze/dyspnea apart from colds, respiratory infections, and eczema. In 72% of the cases, the model accurately discriminated between asthmatic and nonasthmatic children. A clinical risk score was developed (range, 0-55 points). Symptomatic children with a score of less than 10 points had a 3% risk, whereas children with a score of 30 points or greater had a 42% risk of asthma. Conclusion: A risk score based on 8 readily available clinical parameters at the time preschool children first reported asthma-like symptoms predicted the risk of asthma at 7 to 8 years of age.</description>
    </item> <item>
      <title>An economic evaluation of budesonide/formoterol for maintenance and reliever treatment in asthma in general practice (Article)</title>
      <link>http://repub.eur.nl/res/pub/17396/</link>
      <pubDate>2009-09-01T00:00:00Z</pubDate>
      <description>Introduction: In budesonide/formoterol (Symbicort® Turbuhaler®, AstraZeneca, Lund, Sweden) maintenance and reliever therapy (SMART), patients with asthma take a daily maintenance dose of budesonide/formoterol, with the option of taking additional doses for symptom relief instead of a short-acting β2-agonist (SABA). This study assesses the cost-effectiveness of SMART compared with usual care in patients with mild-to-moderate persistent asthma treated by general practitioners in the Netherlands from a societal perspective. Methods: The study was linked to a randomized, active-controlled, open-label, multicenter, 12-month clinical trial, with a prospective collection of resource use. One hundred and two patients ≥18 years with mild-to-moderate persistent asthma and daily inhaled corticosteroids (ICS) prior to the trial were included. SMART was given as two inhalations of budesonide/formoterol (100/6 μg) once daily, plus additional doses as needed. The control group was treated according to guidelines, which prescribe medium daily doses of ICS plus an SABA if needed. A long-acting β2-agonist (LABA) is added if necessary. Effectiveness was measured as the proportion of asthma-control days, Asthma Control Questionnaire (ACQ) scores, the net proportion of patients with relevant ACQ improvement, and the proportion of well-controlled patients. Costs included asthma medication, physician contacts, and absence from work. Results: Mean total costs for SMART were €134.81 lower (95% CI: -€439.48; €44.85). Production losses were €94.10 (95% CI: -€300.60; €0.29) lower for SMART (€10.77 vs. €104.87). No significant differences in health outcomes were seen, with 3.81 fewer asthma-control days per patient-year for SMART (95% CI: -36.8; 30.8), a 0.049 better ACQ score (95% CI: -0.21; 0.29), a 5.8% larger net proportion of improved patients (95% CI: t15.6%; 27.3%), and a 2.1% (95% CI: -25.5; 20.8%) smaller increase in the proportion of well-controlled patients. Conclusions: Treating primary care patients with mild-to-moderate persistent asthma with SMART instead of ICS plus bronchodilators does not affect health outcomes and does not increase costs; therefore, is likely to be an alternative for guideline-directed treatment, from a health and economic perspective.</description>
    </item> <item>
      <title>Effects of pets on asthma development up to 8 years of age: The PIAMA study (Article)</title>
      <link>http://repub.eur.nl/res/pub/24793/</link>
      <pubDate>2009-08-01T00:00:00Z</pubDate>
      <description>Background: Recall bias may provide discrepant relationships of pet exposure with sensitization and asthma development. We studied prospectively effects of pets at home on development of sensitization, asthma and respiratory symptoms from birth up to age 8 years. Methods: Event history analysis was performed on annually registered data of 2951 children, participating in the PIAMA birth cohort study. Results: Children with a cat or dog at home at 3 months of age had a significantly lower prevalence of sensitization to inhalant allergens at age 8, but not of asthma. A cat decreased the risk of house dust mite sensitization at age 8 [odds ratio (OR) = 0.68, 95% confidence interval (CI) 0.49-0.95], a dog of pollen sensitization (OR = 0.49, 95% CI: 0.29-0.83). A cat or dog at home did not significantly affect asthma incidence in each subsequent year. From 2 years of age onwards, the incidence of wheeze (OR = 1.52, 95% CI: 1.12-2.05) and a dry cough at night (OR = 1.28, 95% CI: 1.05-1.57) was higher in children with a dog, whereas removal of a dog increased the risk of developing asthma symptoms. Comparing analyses using prospectively and retrospectively collected data on diagnosed asthma showed important recall bias. Conclusions: Our prospective study shows a protective effect of early presence of pets at home on sensitization to inhalant allergens, but no prevention of asthma development. Furthermore, children with pets had more frequent transient or intermittent asthma symptoms. Parental report of asthma by recall may provide spurious results of these associations. </description>
    </item> <item>
      <title>Smoke exposure interacts with ADAM33 polymorphisms in the development of lung function and hyperresponsiveness (Article)</title>
      <link>http://repub.eur.nl/res/pub/16304/</link>
      <pubDate>2009-06-01T00:00:00Z</pubDate>
      <description>Introduction: ADAM33 is the first identified asthma gene by positional cloning, especially asthma combined with bronchial hyperresponsiveness (BHR). Moreover, ADAM33 is associated with early-life lung function and decline of forced expiratory volume in 1 s (FEV1) in the general population. In utero and postnatal cigarette smoke exposure (CSE) are associated with reduced lung function, and development of BHR and asthma. We hypothesized that this may occur via interaction with ADAM33. Aim: To replicate the role of ADAM33 in childhood lung function and development of BHR and asthma. Furthermore, we investigated gene-environment interaction of ADAM33 with in utero and postnatal CSE in the Dutch PIAMA cohort. Methods: Six ADAM33 single-nucleotide polymorphisms (SNPs) were genotyped. Rint was measured at age 4 and 8 years, FEV1 and BHR at age 8 years; asthma was based on questionnaire data at age 8. Results: In the total cohort, the rs511898 A, rs528557 C, and rs2280090 A alleles increased the risk to develop asthma (+BHR). There existed interaction between in utero but not postnatal CSE and the rs528557 and rs3918396 SNPs with respect to development of BHR, the rs3918396 SNP with Rint at age 8 and the rs528557 SNP with FEV1% predicted. Conclusions: We confirm associations between ADAM33 and the development of asthma (+BHR). This is the first study suggesting that interaction of in utero CSE with ADAM33 results in reduced lung function and the development of BHR, which needs further confirmation.</description>
    </item> <item>
      <title>Overweight and changes in weight status during childhood in relation to asthma symptoms at 8 years of age (Article)</title>
      <link>http://repub.eur.nl/res/pub/24404/</link>
      <pubDate>2009-06-01T00:00:00Z</pubDate>
      <description>Background: Asthma may be more prevalent in overweight children. However, how early overweight and changes in weight status during childhood affect the asthma risk is unclear. Objectives: To investigate overweight and changes in overweight status in children age 1 to 8 years in relation to asthma symptoms in childhood. Methods: We studied 3756 children who participated in a large birth cohort study. The parents reported their children's weight and height, and wheeze, dyspnea, and prescription of inhaled corticosteroids in yearly questionnaires. Sensitization to inhalant allergens and bronchial hyperresponsiveness (BHR) were determined at 8 years. Results: At 8 years, 275 children (7.3%) wheezed, 361 (9.6%) had dyspnea, and 268 (7.1%) had a prescription of inhaled corticosteroids in the preceding year. Children who had a persistent high body mass index (BMI, weight/height2) during childhood or a high BMI at 6 to 7 years had a significantly increased risk of dyspnea (adjusted odds ratio, 1.68; 95% CI, 1.18-2.39, for a high BMI at 6-7 years) and measured BHR (adjusted odds ratio, 1.66; 95% CI, 1.10-2.52) at 8 years. Children with a high BMI at a young age, but who developed a normal BMI at 6 to 7 years, did not have an increased risk of dyspnea or BHR at 8 years. BMI was not associated with sensitization. Conclusion: Children with a current high BMI are at increased risk to have dyspnea and BHR at 8 years. A high BMI at an earlier age is not related to an increased risk if the child has become normal weight at 6 to 7 years. </description>
    </item> <item>
      <title>Exploring the role of polymorphisms in ficolin genes in respiratory tract infections in children (Article)</title>
      <link>http://repub.eur.nl/res/pub/15836/</link>
      <pubDate>2009-03-01T00:00:00Z</pubDate>
      <description>Ficolins are pattern-recognition molecules that appear to be relevant for innate immune defence against infections. The ficolin genes in Caucasians are polymorphic and genetic variations may have functional consequences, both in relation to function and concentration. Low levels of Ficolin-2 have been suggested to associate with recurrent respiratory tract infections (RTI), whereas data on Ficolin-3 are still very limited. We investigated the association between variation in genes encoding Ficolin-2 (FCN2) and Ficolin-3 (FCN3) and frequency of RTI during the first 4 years of life. The study population consisted of 900 children from a large, population-based birth cohort of Dutch children, followed prospectively from birth to 4 years of age. The number of RTI was assessed by annual parental questionnaires. Nine single nucleotide polymorphisms in FCN2 and two in FCN3, all based on functionality or haplotype-tagging characteristics, were determined and haplotypes constructed. We found that single nucleotide polymorphisms in FCN2 and FCN3 were not associated with increased risk of RTI during the first 4 years of life. No difference existed between haplotype-frequencies of FCN2 and FCN3 in children grouped according to the reported number of RTI. In conclusion, at a population level, genetic variation in ficolin genes FCN2 and FCN3 do not seem to contribute to the risk of RTI in Caucasian children.</description>
    </item> <item>
      <title>Asthma at 8 years of age in children born by caesarean section (Article)</title>
      <link>http://repub.eur.nl/res/pub/24911/</link>
      <pubDate>2009-02-01T00:00:00Z</pubDate>
      <description>Background: Caesarean section might be a risk factor for asthma because of delayed microbial colonisation, but the association remains controversial. A study was undertaken to investigate prospectively whether children born by caesarean section are more at risk of having asthma in childhood and sensitisation at the age of 8 years, taking into account the allergic status of the parents. Methods: 2917 children who participated in a birth cohort study were followed for 8 years. The definition of asthma included wheeze, dyspnoea and prescription of inhaled steroids. In a subgroup (n = 1454), serum IgE antibodies for inhalant and food allergens were measured at 8 years. Results: In the total study population, 12.4% (n = 362) of the children had asthma at the age of 8 years. Caesarean section, with a total prevalence of 8.5%, was associated with an increased risk of asthma (OR 1.79; 95% CI 1.27 to 2.51). This association was stronger among predisposed children (with two allergic parents: OR 2.91; 95% CI 1.20 to 7.05; with only one: OR 1.86; 95% CI 1.12 to 3.09) than in children with non-allergic parents (OR 1.36; 95% CI 0.77 to 2.42). The association between caesarean section and sensitisation at the age of 8 years was significant only in children of non-allergic parents (OR 2.14; 95% CI 1.16 to 3.98). Conclusions: Children born by caesarean section have a higher risk of asthma than those born by vaginal delivery, particularly children of allergic parents. Caesarean section increases the risk for sensitisation to common allergens in children with non-allergic parents only.</description>
    </item> <item>
      <title>Polymorphisms in the mannan-binding lectin gene are not associated with questionnaire-reported respiratory tract infections in children (Article)</title>
      <link>http://repub.eur.nl/res/pub/14149/</link>
      <pubDate>2008-12-01T00:00:00Z</pubDate>
      <description>Background. Low mannan-binding lectin (MBL) levels, caused by MBL2 polymorphisms, are suggested to contribute to susceptibility to respiratory tract infections (RTIs), particularly early in life. Large-scale replication of previous associations is needed, however. We investigated the association between MBL2 polymorphisms and the frequency of RTI in a large population-based birth cohort of white children. Methods. The frequency of RTI was prospectively assessed by annual parental questionnaires until children were 4 years of age. Thirteen polymorphisms in MBL2 were determined in 987 Dutch children. Haplotypes, previously shown to be associated with functional levels of MBL, were constructed, and their associations with the frequency of RTI during year 1, year 2, and the first 4 years of life were assessed. High-producing, intermediate-producing, and deficient MBL2 genotypes were defined on the basis of exon 1 and Y/X promoter polymorphisms. Results. No differences were found between investigated polymorphisms and haplotype frequencies in the population as a whole or between the groups with frequent, moderately frequent, or no RTIs reported. Deficient MBL2 genotypes were not associated with an increased risk of RTI (odds ratio, 0.71 [95% confidence interval, 0.25 to 2.05]) during years 1-4 of life. This was also true when year 1 and year 2 were studied separately. Conclusion. These results suggest that, at the population level, MBL2 polymorphisms do not contribute to the risk of questionnaire-reported RTI in white children.</description>
    </item> <item>
      <title>Do differences in childhood diet explain the reduced overweight risk in breastfed children? (Article)</title>
      <link>http://repub.eur.nl/res/pub/14422/</link>
      <pubDate>2008-11-01T00:00:00Z</pubDate>
      <description>Breastfeeding has been associated with a reduced risk of overweight later in life. This study investigates whether differences in diet and lifestyle at 7 years of age between breastfed and formula-fed children can explain the difference in overweight prevalence at 8 years of age. We studied 2,043 Dutch children born in 1996-1997 who participated in the Prevention and Incidence of Asthma and Mite Allergy birth cohort study. Data on breastfeeding duration and diet and lifestyle factors at 7 years were collected using questionnaires. Weight and height were measured at 8 years. Overweight was defined according to international gender- and age-specific standards. Compared to nonbreastfed children (15.5%, n = 316), children breastfed for &gt;16 weeks (38.0%, n = 776) consumed fruit and vegetables significantly more often and meat, white bread, carbonated soft drinks, chocolate bars, and fried snacks less often. Overall, breastfed children were less likely to have an unhealthy diet (adjusted prevalence ratio: 0.77, 95% confidence interval: 0.61-0.98). The associations could only partly be explained by maternal education, maternal overweight, and smoking during pregnancy. At 8 years, 14.5% (n = 297) of the children were overweight. Breastfeeding for &gt;16 weeks was significantly associated with a lower overweight risk at 8 years (adjusted odds ratio: 0.67, 95% confidence interval: 0.47-0.97), and the association hardly changed after adjustment for diet (adjusted odds ratio: 0.71, 95% confidence interval: 0.49-1.03). Breastfed children had a healthier diet at 7 years compared to nonbreastfed children, but this difference could not explain the lower overweight risk at 8 years in breastfed children. © 2008 The Obesity Society.</description>
    </item> <item>
      <title>Increased systemic inflammation is a risk factor for COPD exacerbations (Article)</title>
      <link>http://repub.eur.nl/res/pub/28863/</link>
      <pubDate>2008-02-01T00:00:00Z</pubDate>
      <description>Background: COPD is characterized by episodic increases in respiratory symptoms, so-called exacerbations. COPD exacerbations are associated with an increase in local and systemic inflammation. Data of a previously published study in a well-characterized COPD cohort were analyzed to define predictive factors of acute exacerbations, particularly focusing on systemic inflammation. Objective: To determine if an elevated systemic inflammatory status measured at baseline is related to the occurrence of acute exacerbations in patients with COPD. Methods: The occurrence of moderate (requiring oral prednisolone) and severe exacerbations (requiring hospitalization) was prospectively recorded over 1 year. At the beginning of the study, lung function values (FEV1, FVC, functional residual capacity, and diffusion capacity of the lung for carbon monoxide [DLCO]) and serum levels of C-reactive protein, fibrinogen, lipopolysaccharide binding protein, tumor necrosis factor (TNF)-α, and its soluble receptors (soluble TNF receptors 55 and 75) as markers of systemic inflammation were determined. Results: Two hundred seventy-seven person-years of follow-up were analyzed in the total group of 314 patients: 186 patients were responsible for 411 exacerbations (374 moderate and 37 severe). Multivariate analyses showed that a higher initial fibrinogen level and a lower FEV1predicted a higher rate of both moderate and severe exacerbations. Additional independent predictors of a severe exacerbation were a higher number of prestudy severe exacerbations and lower DLCO. A higher number of prestudy moderate exacerbations was the only additional independent risk factor for the rate of moderate exacerbations. Conclusion: This study demonstrates that besides lung function impairment systemic inflammation manifested by elevated fibrinogen levels is an independent risk factor for exacerbations of COPD. Attenuation of systemic inflammation may offer new perspectives in the management of COPD patients to reduce the burden of exacerbations.</description>
    </item> <item>
      <title>Air pollution and development of asthma, allergy and infections in a birth cohort (Article)</title>
      <link>http://repub.eur.nl/res/pub/36471/</link>
      <pubDate>2007-05-01T00:00:00Z</pubDate>
      <description>Few studies have addressed associations between traffic-related air pollution and respiratory disease in young children. The present authors assessed the development of asthmatic/allergic symptoms and respiratory infections during the first 4 yrs of life in a birth cohort study (n=∼4,000). Outdoor concentrations of traffic-related air pollutants (nitrogen dioxide PM2.5, particles with a 50% cut-off aerodynamic diameter of 2.5 μm and soot) were assigned to birthplace home addresses with a land-use regression model. They were linked by logistic regression to questionnaire data on doctor-diagnosed asthma, bronchitis, influenza and eczema and to self-reported wheeze, dry night-time cough, ear/nose/ throat infections and skin rash. Total and specific immunoglobulin (Ig)E to common allergens were measured in a subgroup (n=713). Adjusted odds ratios (95% confidence intervals) per interquartile pollution range were elevated for wheeze (1.2 (1.0-1.4) for soot), doctor-diagnosed asthma (1.3 (1.0-1.7)), ear/nose/throat infections (1.2 (1.0-1.3)) and flu/serious colds (1.2 (1.0-1.4)). No consistent associations were observed for other end-points. Positive associations between air pollution and specific sensitisation to common food allergens (1.6 (1.2-2.2) for soot), but not total IgE, were found in the subgroup with IgE measurements. Traffic-related pollution was associated with, respiratory infections and some measures of asthma and allergy during the first 4 yrs of life. Copyright </description>
    </item> <item>
      <title>Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma (Article)</title>
      <link>http://repub.eur.nl/res/pub/9170/</link>
      <pubDate>1999-01-01T00:00:00Z</pubDate>
      <description>BACKGROUND: Guidelines state that oral and inhaled corticosteroids are the
      cornerstone of asthma treatment. The effect of both types of treatment can
      be assessed by measuring lung and systemic parameters. Treatment for two
      weeks with either oral prednisolone (30 mg/day), high dose fluticasone
      propionate (2000 microg/day, FP2000), or lower dose FP (500 microg/day,
      FP500), both given by a dry powder inhaler, were compared. METHODS: One
      hundred and twenty patients with asthma were treated for two weeks in a
      double blind parallel group design. Lung function, asthma symptoms, airway
      hyperresponsiveness (PC(20) methacholine and adenosine-5'-monophosphate),
      sputum eosinophil and eosinophilic cationic protein (ECP) levels were
      measured as lung parameters. In addition, morning serum blood cortisol,
      blood eosinophil, and serum ECP levels were measured as systemic
      parameters. RESULTS: PC(20) methacholine and adenosine-5'-monophosphate
      showed significantly greater improvement with FP2000 (1.99 and 4.04
      doubling concentrations (DC), respectively) than prednisolone (0.90 DC, p
      = 0.02; 2.15 DC, p = 0. 05) and marginally more than with FP500 (1.69 and
      3.54 DC). Changes in sputum eosinophil and ECP concentrations showed
      similar trends; the decrease in ECP was significantly greater with FP2000
      than with FP500. In contrast, the systemic parameters of steroid activity
      (cortisol, peripheral blood eosinophils, and serum ECP) decreased to a
      similar extent with FP2000 and prednisolone but significantly less with
      FP500. CONCLUSIONS: Oral prednisolone (30 mg/day) was inferior to FP2000
      in improving airway hyperresponsiveness to both methacholine and AMP, with
      similar trends in forced expiratory volume in one second (FEV(1)), sputum
      eosinophil and ECP concentrations. Systemic effects were similar with
      prednisolone and FP2000 and less with FP500.</description>
    </item> <item>
      <title>Peripheral blood lymphocyte cell subsets in subjects with chronic obstructive pulmonary disease: association with smoking, IgE and lung function (Article)</title>
      <link>http://repub.eur.nl/res/pub/8908/</link>
      <pubDate>1997-01-01T00:00:00Z</pubDate>
      <description>In contrast to the numerous studies which show that lymphocytes play an
      important role in the pathogenesis of asthma, few studies have
      investigated the role of lymphocytes in the pathogenesis of chronic
      obstructive pulmonary disease (COPD). The aim of the present study was to
      investigate lymphocyte subsets in peripheral venous blood of smoking and
      non-smoking COPD patients and healthy controls. The interaction of smoking
      and IgE has also been assessed, and it was investigated whether a lower
      level of FEV1 was associated with changes in lymphocyte subsets. In the
      present study, peripheral venous blood lymphocyte subsets were
      investigated in 42 smoking and non-smoking, non-atopic subjects with a
      clear diagnosis of COPD (43-74 years) who all used bronchodilator therapy
      only, and in 24 normal, healthy control subjects (40-72 years). No
      significant differences in lymphocyte subsets were found when either total
      groups or smoking subjects of both groups were compared. However, the
      percentage of CD8+ lymphocytes (suppressor/ cytotoxic T-cells) was
      significantly higher in the non-smoking COPD subjects compared with the
      non-smoking, healthy control subjects (P &lt; 0.05). In addition, within the
      group of non-smoking COPD subjects, a higher CD4:CD8 ratio was associated
      with a higher FEV1 as a percentage of predicted (% pred.) (r = 0.55, P =
      0.01) and a lower total serum IgE (r = -0.45, P = 0.04). Within the group
      of smoking COPD subjects, a higher FEV1 % pred. was associated with a
      higher percentage of CD19+ lymphocytes (B-cells) (r = 0.65, P &lt; 0.01). The
      present study provides further evidence that the changes in the balance of
      T-cell subsets and IgE synthesis possibly plays a role in the pathogenesis
      of COPD.</description>
    </item> <item>
      <title>Is delayed introduction of inhaled corticosteroids harmful in patients with obstructive airways disease (asthma and COPD)? The Dutch CNSLD Study Group. The Dutch Chronic Nonspecific Lung Disease Study Groups (Article)</title>
      <link>http://repub.eur.nl/res/pub/8614/</link>
      <pubDate>1996-01-01T00:00:00Z</pubDate>
      <description>BACKGROUND: The institution of inhaled corticosteroids is generally
          advocated for effective treatment of patients with asthma. It is yet
          unknown what is the best time to start inhaled corticosteroid therapy and
          especially whether delayed introduction is harmful. PHASE 1: In a previous
          study in patients with asthma and COPD, we found that 2.5 years of
          treatment with a beta 2-agonist plus inhaled corticosteroid (BA + CS) was
          more effective in improving the FEV1 and the provocative concentration of
          histamine causing a 20% reduction in FEV1 (PC20) than treatment with a
          beta 2-agonist plus anticholinergic (BA + AC) or placebo (BA + PL). PHASE
          2: We extended this study with 6 months to investigate whether delayed
          introduction of inhaled CS therapy (800 micrograms beclomethasone
          dipropionate) in the groups previously not treated with inhaled CS (BA +/-
          AC) could also improve FEV1 and PC20 to the same degree. A distinction was
          made between patients with predominantly asthma (high baseline
          reversibility, delta FEV1 &gt; or = 9% of predicted), and predominantly COPD
          (low baseline reversibility, delta FEV1 &lt; 9% of predicted). RESULTS:
          Improvement of FEV1 percent predicted by inhaled CS was comparable both in
          the asthmatics between phase 1 (13.8% predicted) and phase 2 (8.5%
          predicted; p = 0.31) as well as in the patients with COPD (2.5% and 1.5%
          predicted, respectively). PC20, however, increased significantly more in
          the asthmatics in phase 1 (1.77 doubling concentration [DC]) than in phase
          2 (0.79 DC; p = 0.03). Improvement of PC20 in the patients with COPD was
          not significantly higher in phase 1 (0.74 DC) than in phase 2 (0.00 DC; p
          = 0.19). CONCLUSIONS: Our study indicates that although delayed
          introduction of inhaled CS in asthmatics leads to similar improvements in
          FEV1, improvements in PC20 are significantly less. These findings in
          patients with longer-existing asthma concur with other findings in newly
          detected asthma. We suggest that institution of inhaled CS therapy should
          not be postponed in asthmatics with documented airways obstruction and
          reversibility.</description>
    </item>
  </channel>
</rss>